Plus Therapeutics partners with K2bio to develop novel tests for CSF analyses

Plus Therapeutics announced that it has partnered with K2bio to implement novel analysis for cerebrospinal fluid, CSF, tumor and molecular biomarkers for CNS cancers. Initial clinical specimen processing and testing will begin in Q1 2024 in the Company’s ongoing Phase 1 ReSPECT-LM trial of rhenium obisbemeda in patients with leptomeningeal metastases. This trial is currently receiving grant funding through The Cancer Prevention and Research Institute of Texas. The Company expects testing costs to be partially covered under this grant. “The initial diagnosis, therapeutic selection and monitoring of patients with CNS cancers such as leptomeningeal metastases are significant problems in everyday clinical practice,” said Marc Hedrick, M.D., President & Chief Executive Officer of Plus Therapeutics. “To turn these very lethal CNS cancers into treatable diseases, we must ideally address both the diagnostic as well as the therapeutic needs of caregivers and patients. This partnership with K2bio is the next part of our overall strategy to address both needs in parallel.”